Free Trial
NASDAQ:ZYBT

Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis

Zhengye Biotechnology logo
$6.98 +0.28 (+4.18%)
As of 08/22/2025 04:00 PM Eastern

About Zhengye Biotechnology Stock (NASDAQ:ZYBT)

Key Stats

Today's Range
$6.37
$7.14
50-Day Range
$5.21
$9.49
52-Week Range
$3.50
$14.30
Volume
52,925 shs
Average Volume
137,548 shs
Market Capitalization
$329.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZYBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zhengye Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

ZYBT Stock News Headlines

Zhengye Biotechnology Holding Ltd trading resumes
Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
See More Headlines

ZYBT Stock Analysis - Frequently Asked Questions

Zhengye Biotechnology's stock was trading at $4.86 on January 1st, 2025. Since then, ZYBT shares have increased by 43.6% and is now trading at $6.98.

Zhengye Biotechnology (ZYBT) raised $6 million in an IPO on Tuesday, January 7th 2025. The company issued 1,500,000 shares at $4.00 per share. Kingswood Capital Partners served as the underwriter for the IPO.

Zhengye Biotechnology's lock-up period expired on Monday, July 7th. Zhengye Biotechnology had issued 1,500,000 shares in its initial public offering on January 7th. The total size of the offering was $6,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Top institutional investors of Zhengye Biotechnology include Jane Street Group LLC (0.41%), Invesco Ltd. (0.08%) and Geode Capital Management LLC (0.06%).

Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
8/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ZYBT
Previous Symbol
NASDAQ:ZYBT
CIK
1975641
Fax
N/A
Employees
278
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
1.31
Quick Ratio
0.88

Sales & Book Value

Annual Sales
$186.36 million
Price / Sales
1.77
Cash Flow
$0.10 per share
Price / Cash Flow
67.74
Book Value
$1.02 per share
Price / Book
6.84

Miscellaneous

Outstanding Shares
47,166,000
Free Float
N/A
Market Cap
$329.22 million
Optionable
N/A
Beta
N/A
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ZYBT) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners